Recently, small-molecule allosteric modulators of PDE4D that do not completely inhibit enzymatic activity were reported to reduce emesis and have therapeutic benefits of a brain distribution, for such entities as Alzheimer's disease, Huntington's disease, schizophrenia, and depression [54]. This evidence concerns the gene PDE4D and juvenile Huntington disease.